175 related articles for article (PubMed ID: 24871888)
1. Prognosis and prognostic factors of differentiated thyroid carcinoma after the appearance of metastasis refractory to radioactive iodine therapy.
Ito Y; Miyauchi A; Ito M; Yabuta T; Masuoka H; Higashiyama T; Fukushima M; Kobayashi K; Kihara M; Miya A
Endocr J; 2014; 61(8):821-4. PubMed ID: 24871888
[TBL] [Abstract][Full Text] [Related]
2. Radioactive iodine (RAI) therapy for distantly metastatic differentiated thyroid cancer (DTC) in juvenile versus adult patients.
Kammori M; Fukumori T; Sugishita Y; Hoshi M; Shimizu K; Yamada T
Endocr J; 2015; 62(12):1067-75. PubMed ID: 26424174
[TBL] [Abstract][Full Text] [Related]
3. The importance of age over radioiodine avidity as a prognostic factor in differentiated thyroid carcinoma with distant metastases.
Mihailovic J; Stefanovic L; Malesevic M; Markoski B
Thyroid; 2009 Mar; 19(3):227-32. PubMed ID: 19265493
[TBL] [Abstract][Full Text] [Related]
4. Impact of Patient Age and Histological Type on Radioactive Iodine Avidity of Recurrent Lesions of Differentiated Thyroid Carcinoma.
Nakanishi K; Kikumori T; Miyajima N; Takano Y; Noda S; Takeuchi D; Iwano S; Kodera Y
Clin Nucl Med; 2018 Jul; 43(7):482-485. PubMed ID: 29688947
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years.
Brierley J; Tsang R; Panzarella T; Bana N
Clin Endocrinol (Oxf); 2005 Oct; 63(4):418-27. PubMed ID: 16181234
[TBL] [Abstract][Full Text] [Related]
6. LONG-TERM OUTCOMES AND PROGNOSTIC FACTORS IN PATIENTS WITH DIFFERENTIATED THYROID CANCER AND DISTANT METASTASES.
Hirsch D; Levy S; Tsvetov G; Gorshtein A; Slutzky-Shraga I; Akirov A; Robenshtok E; Shimon I; Benbassat CA
Endocr Pract; 2017 Oct; 23(10):1193-1200. PubMed ID: 28704099
[TBL] [Abstract][Full Text] [Related]
7. Prognostic indicators of outcomes in patients with lung metastases from differentiated thyroid carcinoma during long-term follow-up.
Sohn SY; Kim HI; Kim YN; Kim TH; Kim SW; Chung JH
Clin Endocrinol (Oxf); 2018 Feb; 88(2):318-326. PubMed ID: 28972676
[TBL] [Abstract][Full Text] [Related]
8. Recurrent disease in juvenile differentiated thyroid carcinoma: prognostic factors, treatments, and outcomes.
Mihailovic J; Nikoletic K; Srbovan D
J Nucl Med; 2014 May; 55(5):710-7. PubMed ID: 24722527
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy.
Vassilopoulou-Sellin R; Schultz PN; Haynie TP
Cancer; 1996 Aug; 78(3):493-501. PubMed ID: 8697396
[TBL] [Abstract][Full Text] [Related]
10. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.
Piccardo A; Puntoni M; Bottoni G; Treglia G; Foppiani L; Bertoli M; Catrambone U; Arlandini A; Dib B; Altrinetti V; Massollo M; Bossert I; Cabria M; Bertagna F; Giovanella L
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):926-934. PubMed ID: 27966046
[TBL] [Abstract][Full Text] [Related]
11. Risk Stratification Using a Novel Genetic Classifier Including
Jung CK; Jung SH; Jeon S; Jeong YM; Kim Y; Lee S; Bae JS; Chung YJ
Thyroid; 2020 Nov; 30(11):1589-1600. PubMed ID: 32326836
[No Abstract] [Full Text] [Related]
12. OPTIMIZING LENVATINIB THERAPY IN PATIENTS WITH METASTATIC RADIOACTIVE IODINE-RESISTANT DIFFERENTIATED THYROID CANCERS.
Jasim S; Iniguez-Ariza NM; Hilger CR; Chintakuntlawar AV; Ryder MM; Morris JC; Bible KC
Endocr Pract; 2017 Oct; 23(10):1254-1261. PubMed ID: 28816536
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans.
Sabra MM; Grewal RK; Tala H; Larson SM; Tuttle RM
Thyroid; 2012 Sep; 22(9):877-83. PubMed ID: 22827641
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes and risk stratification for papillary thyroid carcinoma presenting with distant metastasis before the era of tyrosine kinase inhibitors.
Matsuzu K; Sugino K; Masudo K; Mori K; Ono R; Yamazaki H; Masaki C; Akaishi J; Kiyomi Yamada H; Tomoda C; Suzuki A; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Takami H; Ito K
Endocr J; 2020 Aug; 67(8):869-876. PubMed ID: 32350192
[TBL] [Abstract][Full Text] [Related]
15. Differentiated thyroid carcinoma in childhood and adolescence-clinical course and role of radioiodine.
Chow SM; Law SC; Mendenhall WM; Au SK; Yau S; Mang O; Lau WH
Pediatr Blood Cancer; 2004 Feb; 42(2):176-83. PubMed ID: 14752883
[TBL] [Abstract][Full Text] [Related]
16. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.
Mazzaferri EL; Jhiang SM
Am J Med; 1994 Nov; 97(5):418-28. PubMed ID: 7977430
[TBL] [Abstract][Full Text] [Related]
17. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.
Scheffel RS; Zanella AB; Dora JM; Maia AL
Thyroid; 2016 Nov; 26(11):1623-1629. PubMed ID: 27549175
[TBL] [Abstract][Full Text] [Related]
18. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies.
Liu YY; van der Pluijm G; Karperien M; Stokkel MP; Pereira AM; Morreau J; Kievit J; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2006 Jun; 64(6):617-24. PubMed ID: 16712662
[TBL] [Abstract][Full Text] [Related]
19. Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope.
Podnos YD; Smith DD; Wagman LD; Ellenhorn JD
J Surg Oncol; 2007 Jul; 96(1):3-7. PubMed ID: 17567872
[TBL] [Abstract][Full Text] [Related]
20. Radioactive iodine ablation does not prevent recurrences in patients with papillary thyroid microcarcinoma.
Kim HJ; Kim NK; Choi JH; Kim SW; Jin SM; Suh S; Bae JC; Min YK; Chung JH; Kim SW
Clin Endocrinol (Oxf); 2013 Apr; 78(4):614-20. PubMed ID: 22957654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
